GlassScriptPhysician profile
Kimberly Dao
NPI 1235633504
$1,018.94
in general payments reported to CMS, 2019-2025
19 companies · $677 in 2025
The $677 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $342 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $161.40 | 2024-2025 | |
| Abbvie INC. | $149.69 | 2024-2025 | |
| Lilly USA, LLC | $98.63 | 2024-2025 | Zepbound, Mounjaro, Kisunla |
| Novo Nordisk INC | $93.69 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Dynavax Technologies Corporation | $70.70 | 2024-2025 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $70.64 | 2025 | |
| Exact Sciences Corporation | $59.28 | 2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $49.21 | 2025 | Watchman Access System |
| Glaxosmithkline, LLC. | $40.01 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $35.40 | 2024 | Airsupra, Farxiga |
| Phathom Pharmaceuticals, INC. | $35.25 | 2024 | Voquezna |
| Amgen INC. | $35.01 | 2024-2025 | Evenity, Prolia, Repatha |
| Merck Sharp & Dohme LLC | $19.85 | 2025 | Gardasil 9, Capvaxive |
| Janssen Pharmaceuticals, INC | $19.11 | 2024 | Xarelto |
| Cranial Technologies, INC | $18.37 | 2025 | Doc Band |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $17.44 | 2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $15.57 | 2024 | |
| Antares Pharma, INC. | $15.27 | 2025 | Xyosted |
| Dexcom, INC. | $14.42 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Dao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.